B. Riley Securities Maintains Buy on MediciNova, Lowers Price Target to $5
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
B. Riley Securities analyst Mayank Mamtani maintains MediciNova (NASDAQ:MNOV) with a Buy and lowers the price target from $6 to $5.
B. Riley Securities analyst Mayank Mamtani maintains MediciNova (NASDAQ:MNOV) with a Buy and lowers the price target from $6 to $5.